The efficacy of AUCATZYL was evaluated in an open-label, multi-center, single-arm study (FELIX study; NCT04404660). The study enrolled patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Eligible patients were adults with refractory ALL, first relapse following a remission lasting ≤ 12 months, relapsed or refractory ALL after two or more prior lines of systemic therapy, or relapsed or refractory ALL at least greater than 3 months after allogeneic stem cell transplantation (SCT) and had disease burden of ≥ 5% blasts in bone marrow at screening. The study excluded patients with isolated extramedullary disease, active or serious infections requiring systemic antimicrobials, active graft versus host disease, history or presence of central nervous system (CNS) disorders. Treatment was administered in the in-patient setting and consisted of lymphodepleting chemotherapy (fludarabine 30 mg/m2 IV daily for 4 days; cyclophosphamide 500 mg/m2 IV daily for 2 days starting with first dose of fludarabine) followed by AUCATZYL as a split dose infusion with a total recommended dose of 410 × 106 CD19 CAR-positive viable T cells.
A total of 112 patients were enrolled and underwent leukapheresis; 18 (16%) of whom discontinued without receiving AUCATZYL infusion due to the following: death (n=11), adverse event (n=1), physician decision (n=1), and manufacturing failure (n=5). Among the remaining 94 patients who received at least one infusion of AUCATZYL, 65 patients had ≥ 5% blasts in the bone marrow after screening and prior to the start of the lymphodepletion therapy, and received a conforming product, qualifying them as efficacy-evaluable patients.
The population characteristics of efficacy-evaluable patients were as follows: median age was 51 years (range: 20 to 77 years) with 7 patients (11%) ≤ 25 years of age and 14 patients (22%) ≥ 65 years of age, 35 patients (54%) were female, 47 patients (72%) were White, 8 patients (12%) were Asian and 1 patient (2%) was Black or African American. Twenty-one patients (32%) were of Hispanic or Latino ethnicity.
At enrollment, 35 patients (54%) were refractory to the last prior line of therapy, and 32 patients (49%) relapsed to first-line therapy within 12 months. The median number of prior lines of therapy was 2 (range: 1 to 6). Thirty-five patients (54%) received either blinatumomab or inotuzumab ozogamicin and 10 patients (15%) received both blinatumomab and inotuzumab ozogamicin, 22 (34%) patients received prior SCT therapy, 17 (26%) patients had Ph+ ALL and 13 (20%) patients had extramedullary disease. Fifty-nine patients (91%) received bridging therapy between leukapheresis and lymphodepleting chemotherapy.
The median dose was 410 × 106 CD19 CAR-positive viable T cells (range: 10 to 418 × 106 CD19 CAR-positive viable T cells). Fifty-eight patients (89%) received the target dose of 410 × 106 CD19 CAR-positive viable T cells (± 25%). Five patients (8%) only received the first dose, primarily due to adverse events (5%). The median time from leukapheresis to product release was 20 days (range: 17 to 23 days) and the median time from leukapheresis to AUCATZYL infusion was 35 days (range: 26 to 74 days).
The major efficacy outcome measures were rate and duration of complete remission within 3 months after infusion. Additional outcome measures were rate and duration of overall complete remission which includes complete remission and complete remission with incomplete hematologic recovery, at any time. The efficacy results are summarized in Table 6 below.
Table 6: Efficacy Results for FELIX Study| Endpoint | Efficacy-Evaluable N=65 n (%) | All Leukapheresed N=112 n (%) |
|---|
| CI=confidence interval; NR=not reached. |
| Complete Remission (within 3 months) rate | | |
| n (%) | 27 (42%) | 40 (36%) |
| [95% CI] | [29%, 54%] | (27%, 45%) |
| Duration (months), median [95% CI] | 14.1 [6.1, NR] | 14.1 (6.2, NR) |
| (Range in months) | (0.5+, 21.2) | (0.5+, 21.2) |
| Overall Complete Remission (At Anytime) rate
| | |
| n (%) | 41 (63%) | 60 (54%) |
| [95% CI] | [50%, 75%] | [44%, 63%] |
| Duration (months), median [95% CI] | 14.1 [6.2, NR] | 14.1 [8.1, NR] |
| (Range in months) | (0.03+, 21.2) | (0.03+, 21.2) |
Among patients in the efficacy-evaluable population who achieved a best response of complete remission "At Anytime" (N=33; 51%), the median duration for remission was 14.1 months (95% confidence interval [CI]: 6.1, not reached [NR]). Among patients in the efficacy-evaluable population in whom best response was complete remission with incomplete hematologic recovery "At Anytime" (N=8; 12%), the median duration of remission was 10.5 months (95% CI: 1.8, NR).